What's Happening?
Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified the receptor for advanced glycation end-products (RAGE) as a key factor in the increased metastasis of breast cancer in older patients. The study, conducted on both mouse
models and human breast cancer samples, found that RAGE amplifies inflammatory signaling, which becomes more active with metastatic progression. The research suggests that inhibiting RAGE could serve as a well-tolerated adjunctive therapy for older breast cancer patients. The study highlights that aging significantly increases breast cancer metastasis, with RAGE playing a crucial role in this process. The findings are published in Communications Biology and suggest that targeting RAGE could mitigate age-related cancer progression.
Why It's Important?
The study's findings are significant as they address a major gap in understanding how aging affects cancer progression. With age being a primary risk factor for breast cancer, the research provides insights into why older patients experience worse outcomes. The identification of RAGE as a mechanistic link between aging and metastasis opens new avenues for therapeutic interventions. This could lead to improved treatment options for older patients, who often face limited choices due to the toxicity of existing therapies. The potential repurposing of RAGE inhibitors, like TTP488, could offer a safer alternative to combat cancer metastasis in the elderly.
What's Next?
A clinical study is underway at Lombardi to evaluate the safety and cognitive outcomes of TTP488 in breast cancer patients undergoing chemotherapy. The drug has shown a favorable safety profile in previous studies, supporting its potential for repurposing. If successful, this could lead to broader clinical applications of RAGE inhibitors in treating age-related cancer metastasis. The ongoing research aims to further explore the role of RAGE in other age-related diseases, potentially expanding its therapeutic relevance beyond cancer.
